LAVAL, Quebec, Nov. 11, 2010 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX-V:NTB) and Neptune's management announce their intention to exercise warrants of Acasti Pharma Inc. ("Acasti").
In accordance with the strategic plan initially established in 2008 for the development of Acasti, Neptune is taking another step forward in the financing of Acasti's activities by exercising 2,000,000 Series III Acasti Warrants at a price of $0.40 per warrant representing total proceeds of $800,000 for Acasti.
Board members and officers also confirmed their intention to exercise a minimum of 189,577 Series II Acasti Warrants at a price of $0.40 per warrant prior to their expiration on November 17, 2010. In addition, a company controlled by an officer of Neptune has made arrangements to have 481,750 Series II Acasti Warrants exercised. The above exercises of warrants will thus result in the issuance of a minimum of 671,327 Acasti shares representing additional proceeds of $268,531.
About Neptune Technologies & Bioressources Inc.
Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 20 countries worldwide. Neptune is the mother company of Acasti and NeuroBioPharm.
Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular conditions within the over-the-counter, medical food and prescription drug markets.
NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.
CONTACT: Neptune Technologies & Bioressources Inc. Andre Godin, V.P. Administration and Finance +1 (450) 687.2262 a.godin@neptunebiotech.com www.neptunebiotech.com Acasti Pharma Inc. Tina Sampalis, President +1 (450) 686.4555 t.sampalis@acastipharma.com www.acastipharma.com CEOcast Dan Schustack +1 (212) 732-4300 dschustack@ceocast.com www.ceocast.com Howard Group Bob Beaty 1 (888) 221-0915 bob@howardgroupinc.com www.howardgroupinc.com